CO6940427A2 - Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio - Google Patents

Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio

Info

Publication number
CO6940427A2
CO6940427A2 CO14090473A CO14090473A CO6940427A2 CO 6940427 A2 CO6940427 A2 CO 6940427A2 CO 14090473 A CO14090473 A CO 14090473A CO 14090473 A CO14090473 A CO 14090473A CO 6940427 A2 CO6940427 A2 CO 6940427A2
Authority
CO
Colombia
Prior art keywords
phenylimidazol
ethylamine
derivatives
useful
sodium channel
Prior art date
Application number
CO14090473A
Other languages
English (en)
Inventor
Sharanjeet Kaur Bagal
Mark Ian Kemp
Charles Duncan Miller
Yoshihisa Murata
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6940427(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CO6940427A2 publication Critical patent/CO6940427A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CO14090473A 2011-10-26 2014-04-28 Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio CO6940427A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26

Publications (1)

Publication Number Publication Date
CO6940427A2 true CO6940427A2 (es) 2014-05-09

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14090473A CO6940427A2 (es) 2011-10-26 2014-04-28 Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio

Country Status (28)

Country Link
US (1) US9079878B2 (es)
EP (1) EP2771335A2 (es)
JP (1) JP5946538B2 (es)
KR (1) KR101586966B1 (es)
CN (1) CN103906746B (es)
AP (1) AP2014007579A0 (es)
AU (1) AU2012328034B2 (es)
BR (1) BR112014009102A2 (es)
CA (1) CA2850925C (es)
CL (1) CL2014000956A1 (es)
CO (1) CO6940427A2 (es)
CR (1) CR20140185A (es)
CU (1) CU20140046A7 (es)
DO (1) DOP2014000085A (es)
EA (1) EA023375B1 (es)
EC (1) ECSP14013324A (es)
GT (1) GT201400079A (es)
HK (1) HK1198650A1 (es)
IL (1) IL232267A (es)
MD (1) MD20140037A2 (es)
MX (1) MX337469B (es)
NI (1) NI201400031A (es)
PE (1) PE20141682A1 (es)
SG (1) SG11201401032YA (es)
TN (1) TN2014000147A1 (es)
UA (1) UA109220C2 (es)
WO (1) WO2013061205A2 (es)
ZA (1) ZA201402281B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2755980T3 (da) * 2011-09-14 2020-01-27 Dow Agrosciences Llc Fremgangsmåder og systemer til dannelse boronsyre og mellemprodukter deraf
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
EP3209303A4 (en) 2014-10-24 2017-08-30 Avectas Limited Delivery across cell plasma membranes
KR20170117170A (ko) 2015-02-19 2017-10-20 퍼듀 퍼머 엘피 위 배출을 감소시키기 위한 방법 및 조성물
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
AU2016380836A1 (en) 2015-12-30 2018-07-12 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
EP3481857A1 (en) 2016-07-06 2019-05-15 Crispr Therapeutics AG Materials and methods for treatment of pain related disorders
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
ES2927712T3 (es) 2017-05-16 2022-11-10 Vertex Pharma Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4346818A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
NZ550769A (en) * 2004-05-07 2010-06-25 Warner Lambert Co 3- or 4-Monosubstituted phenol and thiophenol derivatives useful as H3 ligands
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
MX2007005069A (es) 2004-10-27 2007-06-25 Schering Corp Composiciones y metodos para la inhibicion del acido nucleico corto de interferencia de nav1.8.
NZ567540A (en) * 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
MX2009004233A (es) 2006-10-18 2009-08-12 Pfizer Prod Inc Compuestos de biaril eter urea.
DE602008000809D1 (de) 2007-03-23 2010-04-29 Icagen Inc Ionenkanal-Hemmer
CN101675040A (zh) 2007-05-03 2010-03-17 辉瑞有限公司 作为钠通道调节剂的2-吡啶甲酰胺衍生物
CA2685952C (en) 2007-05-03 2012-03-13 Pfizer Limited N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
NI201400031A (es) 2014-10-01
MX337469B (es) 2016-03-02
IL232267A (en) 2016-10-31
CA2850925A1 (en) 2013-05-02
AU2012328034A1 (en) 2014-05-15
CR20140185A (es) 2014-06-03
NZ623090A (en) 2015-10-30
CA2850925C (en) 2017-01-10
JP2014530900A (ja) 2014-11-20
CN103906746B (zh) 2015-12-09
EA023375B1 (ru) 2016-05-31
BR112014009102A2 (pt) 2017-04-18
CN103906746A (zh) 2014-07-02
AP2014007579A0 (en) 2014-04-30
WO2013061205A3 (en) 2013-06-27
PE20141682A1 (es) 2014-11-14
CL2014000956A1 (es) 2014-07-18
DOP2014000085A (es) 2014-08-31
KR20140069234A (ko) 2014-06-09
AU2012328034B2 (en) 2015-04-23
SG11201401032YA (en) 2014-07-30
MX2014004738A (es) 2014-08-01
EP2771335A2 (en) 2014-09-03
UA109220C2 (uk) 2015-07-27
WO2013061205A2 (en) 2013-05-02
US9079878B2 (en) 2015-07-14
MD20140037A2 (ro) 2014-08-31
EA201490864A1 (ru) 2014-08-29
CU20140046A7 (es) 2014-10-02
KR101586966B1 (ko) 2016-01-19
WO2013061205A8 (en) 2014-03-27
GT201400079A (es) 2015-06-02
IL232267A0 (en) 2014-06-30
ZA201402281B (en) 2015-11-25
HK1198650A1 (en) 2015-05-22
US20140296313A1 (en) 2014-10-02
JP5946538B2 (ja) 2016-07-06
TN2014000147A1 (fr) 2015-09-30
ECSP14013324A (es) 2014-05-31

Similar Documents

Publication Publication Date Title
CO6940427A2 (es) Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio
BR112013028886A2 (pt) compostos heterocíclicos fundidos como moduladores dde canal de sódio
BR112013032361A2 (pt) benzoxazepinonas fundidas como moduladores de canal iônico
BR112013032027A2 (pt) compostos heterocíclicos fundidos como moduladores de canal de íon
SMT201600162B (it) Pirrolopirazina-ammidi piperidin spirocicliche come modulatori dei canali ionici
EP2769263A4 (en) ADJUSTABLE GOGGLES WITH REPLACEABLE LENS FOR FOG PREVENTION
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
CR20130403A (es) Derivados de fluoro-piridinona útiles como agentes antibacterianos
SMT201600410B (it) Modulatori diidropirazolici di gpr40
CO6930368A2 (es) Composiciones de yodo-povidona estable
AR092198A1 (es) Derivados de pirazolopirimidinas
EP2531024A4 (en) 4- (N-AZACYCLOALKYL) ANILIDE DERIVATIVES AS MODULATORS OF POTASSIUM CHANNELS
BR112014004779A2 (pt) formulações de derivados de decitabina
BR112014000656A2 (pt) formulações de vacina parenteral contra norovírus
UY33909A (es) Metodo para producir fibra de lignina
CO6900143A2 (es) Derivados de étinilo como moduladores alostéricos de mglur5
CO6960557A2 (es) Derivados de 2-yodo-imidazol
CO6920301A2 (es) Derivados insecticidas de 2-metoxibenzamida
BR112013025721A2 (pt) métodos de fabricação de elementos absorventes volumosos
CO6870027A2 (es) Composición de recipiente de vidrio
BR112014009761A2 (pt) composição oftálmica
UY34286A (es) Diagnóstico de vacuna mejorado
BR112014000259A2 (pt) bloqueadores de canais de sódio dependentes de voltagem
UY34403A (es) Preparación de liberación sostenida

Legal Events

Date Code Title Description
FG Application granted